德康醫療股票討論區

DexCom's start of profitability could signal fast earnings growth, justifying strong share price gains. Despite recent slowdown, the company might continue to execute with prowess.

DexCom's recent profitability and reinvestment are positive signs. The stock's 225% return over five years indicates investors recognize these changes. If maintained, DexCom could have a promising future.

DexCom's high P/S ratio is justified by its superior revenue growth and future prospects. Investors' confidence in the company's future revenues is reflected in this ratio, suggesting the share price won't fall significantly soon.

Despite DexCom's higher-than-average return on equity, the company's high debt levels could pose a significant risk. While debt can boost return on equity, it is only justifiable when a company can generate substantial returns from it.

Baird analysts anticipate Insulet's earnings to grow faster than their annual sales of approx. 20%. DexCom's margins predicted to expand with sales growth over 20% annually before GLP-1s impact. Boston Scientific considered a top-level medtech enterprise by Baird's Rescott.

Inflation data is on watch and expected to fall in Australia and the US. But expect smart money to flow into healthcare stocks as job growth is slowing and surplus income is falling. We cover healthcare stocks to maybe jab into your portfolio. Plus, the potential OPEC+ meeting outcomes with stocks to watch given the oil price is in 'oversold' territory'
1- US inflation to fall under the Fed's target. Wow. Australia's inf...